Work

A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with Myelofibrosis Refractory or Intolerant to JAK Inhibitors

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-153940

Authors: Srinivas K. Tantravahi, Soo Jin Kim, Divya Sundar, Ami B. Patel, Anthony D. Pomicter, Kenneth M. Boucher, Kamal Chamoun, Jatin Shah, Anton Rets, Tracy I. George, Josef T. Prchal, Michael W. Deininger

Institutions: University of Utah, Huntsman Cancer Institute, Karyopharm Therapeutics (United States), ARUP Laboratories (United States)

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3211629783

Cites:

Cited by: 13

Related to: 10